Covington & Burling, Latham Lead UCB's $2B Ra Pharma Buy

Law360 (October 10, 2019, 10:22 AM EDT) -- Belgium's UCB, advised by Covington & Burling, unveiled plans Thursday to snap up Latham & Watkins-led clinical stage biotech company Ra Pharma in a $2.1 billion deal, as UCB looks to bolster its potential in the rare disease space.

UCB expects the takeover of Ra Pharmaceuticals Inc. to bring a proprietary chemistry platform that seeks to develop new therapies for treating serious diseases, according to a statement. 

"Ra Pharma is an excellent strategic fit addressing multiple areas of UCB's patient value growth strategy. Upon closing, the acquisition will add to our strong internal growth opportunities — six potential product launches in...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS